Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
2002 2
2003 4
2004 2
2005 3
2006 3
2007 5
2008 7
2009 1
2010 4
2011 6
2012 6
2013 1
2014 7
2015 3
2016 9
2017 5
2018 4
2019 10
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. James ND, et al. Among authors: russell jm. Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. Lancet. 2016. PMID: 26719232 Free PMC article. Clinical Trial.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Parker CC, et al. Among authors: russell jm. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21. Lancet. 2018. PMID: 30355464 Free PMC article. Clinical Trial.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators. James ND, et al. Among authors: russell jm. N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3. N Engl J Med. 2017. PMID: 28578639 Free PMC article. Clinical Trial.
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW; STAMPEDE Investigators. Hoyle AP, et al. Among authors: russell m. Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23. Eur Urol. 2019. PMID: 31447077
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MK, Sydes MR; STAMPEDE Investigators. James ND, et al. Among authors: russell jm. JAMA Oncol. 2016 Mar;2(3):348-57. doi: 10.1001/jamaoncol.2015.4350. JAMA Oncol. 2016. PMID: 26606329 Free PMC article. Clinical Trial.
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ. Woods BS, et al. Among authors: russell jm. Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14. Eur Urol Oncol. 2018. PMID: 31158087 Free PMC article. Clinical Trial.
Nanofiber-hydrogel composite-mediated angiogenesis for soft tissue reconstruction.
Li X, Cho B, Martin R, Seu M, Zhang C, Zhou Z, Choi JS, Jiang X, Chen L, Walia G, Yan J, Callanan M, Liu H, Colbert K, Morrissette-McAlmon J, Grayson W, Reddy S, Sacks JM, Mao HQ. Li X, et al. Among authors: martin r. Sci Transl Med. 2019 May 1;11(490):eaau6210. doi: 10.1126/scitranslmed.aau6210. Sci Transl Med. 2019. PMID: 31043572
Drug repositioning in epilepsy reveals novel antiseizure candidates.
Brueggeman L, Sturgeon ML, Martin RM, Grossbach AJ, Nagahama Y, Zhang A, Howard MA 3rd, Kawasaki H, Wu S, Cornell RA, Michaelson JJ, Bassuk AG. Brueggeman L, et al. Among authors: martin rm. Ann Clin Transl Neurol. 2018 Dec 11;6(2):295-309. doi: 10.1002/acn3.703. eCollection 2019 Feb. Ann Clin Transl Neurol. 2018. PMID: 30847362 Free PMC article.
Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop.
Osoegawa K, Vayntrub TA, Wenda S, De Santis D, Barsakis K, Ivanova M, Hsu S, Barone J, Holdsworth R, Diviney M, Askar M, Willis A, Railton D, Laflin S, Gendzekhadze K, Oki A, Sacchi N, Mazzocco M, Andreani M, Ameen R, Stavropoulos-Giokas C, Dinou A, Torres M, Dos Santos Francisco R, Serra-Pages C, Goodridge D, Balladares S, Bettinotti MP, Iglehart B, Kashi Z, Martin R, Saw CL, Ragoussis J, Downing J, Navarrete C, Chong W, Saito K, Petrek M, Tokic S, Padros K, Beatriz Rodriguez M, Zakharova V, Shragina O, Marino SR, Brown NK, Shiina T, Suzuki S, Spierings E, Zhang Q, Yin Y, Morris GP, Hernandez A, Ruiz P, Khor SS, Tokunaga K, Geretz A, Thomas R, Yamamoto F, Mallempati KC, Gangavarapu S, Kanga U, Tyagi S, Marsh SGE, Bultitude WP, Liu X, Cao D, Penning M, Hurley CK, Cesbron A, Mueller C, Mytilineos J, Weimer ET, Bengtsson M, Fischer G, Hansen JA, Chang CJ, Mack SJ, Creary LE, Fernandez-ViƱa MA. Osoegawa K, et al. Among authors: martin r. Hum Immunol. 2019 Apr;80(4):228-236. doi: 10.1016/j.humimm.2019.01.009. Epub 2019 Feb 6. Hum Immunol. 2019. PMID: 30738112 Free PMC article. Review.
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E. Wilkins A, et al. Among authors: russell m. Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28. Lancet Oncol. 2015. PMID: 26522334 Free PMC article. Clinical Trial.
75 results
Jump to page
Feedback